Disease Landscape and Forecast Insights

The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral…

Although the schizophrenia drug market is crowded, few, if any, effective therapies are available in the United States and Europe to treat the disease’s negative symptoms (e.g., blunted affect,…

Antipsychotics are the cornerstone of schizophrenia treatment, with the crowded atypical and typical antipsychotic drug classes resulting in a complex treatment algorithm. Given the genericization…

Antipsychotics are the standard of care for treating schizophrenia, with oral atypical antipsychotics (e.g., olanzapine, risperidone) experiencing preferential use. Because of the heterogeneity of…

Despite the availability of multiple oral atypical antipsychotics in the United States, long-acting depot formulations of atypical antipsychotics offer a compelling advantage because of their less…

The schizophrenia therapy market is mature and very crowded given the presence of numerous atypical and typical antipsychotic agents, including the continued genericization of key oral therapies,…

Market Outlook Atypical antipsychotics—the cornerstone of schizophrenia treatment—are available as oral and long-acting depot formulations in the United States. Many of the oral atypical…

Schizophrenia is an often disabling psychiatric disease whose core treatment consists of years up to a lifetime of treatment with antipsychotics (older typical antipsychotics or newer atypical…

As of 2016, over 2 million people across the EU5 countries have a diagnosis of schizophrenia. Many of the oral atypical antipsychotic therapies used to treat the symptoms of schizophrenia are…

Schizophrenia and major depressive disorder (MDD) are disabling psychiatric conditions that are linked to a heavy economic and disease burden on society and patients as well as their caregivers…

The prevalence of the often disabling psychiatric diseases schizophrenia and major depressive disorder (MDD) is growing in Brazil and Mexico. Antipsychotics (older typical or newer atypical…

The positive symptoms of schizophrenia (e.g., hallucinations, delusions) are a symptom domain of schizophrenia that affects approximately 83% of the 3.2 million diagnosed prevalent cases of…